Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020067930 - COMPOUNDS FOR TREATING TYPE 2 DIABETES

Publication Number WO/2020/067930
Publication Date 02.04.2020
International Application No. PCT/RU2019/000686
International Filing Date 27.09.2019
IPC
C07D 471/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
08Bridged systems
A61K 31/4245 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4245Oxadiazoles
A61K 31/439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 5/50 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
CPC
A61K 31/4245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4245Oxadiazoles
A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61P 5/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
C07D 471/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
08Bridged systems
Applicants
  • ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НЕОБИОТЕК" OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU "NEOBIOTEK" [RU]/[RU]
Inventors
  • ТРУХАН, Владимир Михайлович TRUKHAN, Vladimir Mikhailovich
  • ЗИНЕВИЧ, Татьяна Витальевна ZINEVICH, Tatyana Vitalievna
  • МАСЛОВ, Иван Олегович MASLOV, Ivan Olegovich
  • КИРИЧЕНКО, Ольга Геннадьевна KIRICHENKO, Olga Gennadievna
Agents
  • КОВАЛЕНКО, Валентина Васильевна KOVALENKO, Valentina Vasilievna
Priority Data
201813426628.09.2018RU
Publication Language Russian (RU)
Filing Language Russian (RU)
Designated States
Title
(EN) COMPOUNDS FOR TREATING TYPE 2 DIABETES
(FR) COMPOSÉS POUR LE TRAITEMENT DU DIABÈTE SUCRÉ DE TYPE 2
(RU) СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА 2-ГО ТИПА
Abstract
(EN)
The invention relates to the field of organic chemistry, and in particular to new compounds that are amides of beta-amino acids of stereoisomers of 3-azabicyclo[2.2.1]heptene-2-carbonitrile of formula (I) or pharmaceutically acceptable salts thereof, where R1 = H - hydrogen; C1-5 - alkyl; R2 = H - hydrogen; C1-5 - alkyl; benzyl (C6H5-CH2) substituted with one, two or three halogen atoms (F); R3 = H - hydrogen; adamantyl, in which each carbon can have a substituent selected from: hydroxy (OH-); benzyl (C6H5-CH2), in which there may be substituents: hydroxy (OH-) and one halogen (F). The invention also relates to an amide of beta-amino acids of stereoisomers of 3-(3-azabicyclo[2.2.1]heptan-2-yl)-1,2,4-oxadiazole of formula (II) and an amide of beta-amino acids of stereoisomers of 5-(3-azabicyclo[2.2.1]heptan-2-yl)-1,2,4-oxadiazole of formula (III) and a dipeptidyl peptidase-4 inhibitor based on said compounds. Technical result: creation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
(FR)
L'invention se rapporte au domaine de la chimie organique et concerne de nouveaux composés qui consistent en des amides de beta-aminoacides de stéréoisomères de 3-azabicyclo[2.2.1 ]hepten-2-carbonitrile selon la formule (I) ou de leurs sels pharmaceutiquement acceptables, dans laquelle: Rl = Н - hydrogène; С 1-5 - alkyle; R2 = Н - hydrogène; С 1-5 - alkyle; benzyle (С6Н5-СН2), substitué par un, deux ou trois atomes d'halogène (F); R3 = Н - hydrogène; adamantyle, dans lequel chaque atome de carvone peut avoir un substituant choisi parmi: hydroxy(ОН-); benzyl(С6Н5-СН2), dans lequel des substituants peuvent être présents: hydrox- (ОН-) ou un halogène (F). L'invention concerne également un amide de beta-aminoacides de stéréoisomères de 3-(3-azabicyclo[2.2.1]heptan-2-yl)-1,2,4-oxadiazole de la formule (II) et un amide de beta-aminoacides de stéréoisomères de 5-(3-azabicyclo[2.2.1]heptan-2-yl)-1,2,4-oxadiazole selon la formule (III), ainsi qu'un inhibiteur de dipeptidylpeptidase-4 à base de ces composés. Le résultat technique consiste en la production d'inhibiteurs de dipeptidylpeptidase-4 pour traiter des patients souffrant du diabète sucré de type 2.
(RU)
Изобретение относится к области органической химии, а именно к новым соединениям, представляющим собой амиды бета-аминокислот стереоизомеров 3-азабицикло[2.2.1]гептен-2- карбонитрила формулы (I) или к их фармацевтически приемлемым солям, где Rl = Н - водород; С 1-5 - алкил; R2 = Н - водород; С 1-5 - алкил; бензил (С6Н5-СН2), замещенный одним, двумя или тремя атомами галогена (F); R3 = Н - водород; адамантил, в котором каждый углерод может иметь заместитель, выбранный из: гидрокси (ОН-); бензил (С6Н5-СН2), в котором могут быть заместители: гидрокси- (ОН-) и один галоген (F). Также изобретение относится к амиду бета- аминокислот стереоизомеров 3-(3-азабицикло[2.2.1]гептан-2-ил)-1,2,4-оксадиазола формулы II и амиду бета- амин окисл от стереоизомеров 5-(3-азабицикло[2.2.1]гептан-2-ил)-1,2,4-оксадиазола формулы III и ингибитору дипептидилпептидазы-4 на основе указанных соединений. Технический результат: создание ингибиторов дипептидилпептидазы-4 для лечения больных сахарным диабетом 2-го типа.
Latest bibliographic data on file with the International Bureau